journal article·2025-10Open access

Exosomal CCT6A Secreted by Cancer‐Associated Fibroblasts Interacts with β‐Catenin to Enhance Chemoresistance and Tumorigenesis in Gastric Cancer

Hui Sun, Tianqi Zhang, Xiaoyan Zhang, Yingxue Liu, Xu Wang, Xin Wang, Cong Tan, Shujuan Ni, Weiwei Weng, Meng Zhang, Lei Wang, Dan Huang, Xiaoyu Wang, Wenfeng Wang, Weiqi Sheng, Mi‐die Xu

Advanced Science· Volume 12· Issue 38

Abstract

Abstract Cancer‐associated fibroblasts (CAFs) are pivotal components of the tumor microenvironment that drive gastric cancer (GC) progression and chemoresistance. Here, CCT6A is identified as a CAF‐derived factor whose high expression is positively associated with GC progression and plays a key regulatory role in stemness, chemoresistance, and glucose metabolism. In a co‐culture system of CAFs and cancer cells, it is discovered that CCT6A is transferred from CAFs to tumor cells mainly via exosomal transport, thereby enhancing stemness, chemoresistance, and glycolysis. Mechanistically, CCT6A interacts with β‐catenin, inducing its phosphorylation and nuclear translocation, which subsequently leads to transcriptional suppression of the glycolysis inhibitors DDIT4 and TXNIP through c‐Myc activation. Furthermore, a feedforward regulatory loop is uncovered in which the CCT6A pseudogene CCT6P1 acts as a competitive endogenous RNA (ceRNA) by sequestering miR‐922, thereby stabilizing CCT6A expression, while c‐Myc co‐activates both CCT6A and CCT6P1, amplifying oncogenic signaling. Collectively, the findings not only reveal the pivotal mediator of CAF‐secreted CCT6A in orchestrating stemness, chemoresistance, and metabolic reprogramming in GC but also highlight its dual utility as a diagnostic biomarker and therapeutic target.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Galectins and Cancer Biology · Extracellular vesicles in disease · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pathology Fudan University Shanghai Cancer Center Shanghai 200032 China

Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 China

Institute of Pathology Fudan University Shanghai 200032 China

Experiment Center for Science and Technology Shanghai University of Traditional Chinese Medicine Shanghai 201203 China

Shanghai Urological Cancer Institute Cancer Institute Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 China

Funding

Innovative Research Group Project of the National Natural Science Foundation of China · Natural Science Foundation of Shanghai Municipality

References (46)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1186/s40880-019-0349-910.1186/s40880-019-0349-9 ↗
3. 10.1186/s13045-023-01451-310.1186/s13045-023-01451-3 ↗
4. 10.1016/j.jare.2024.05.03110.1016/j.jare.2024.05.031 ↗
5. 10.1038/s41419-022-05320-810.1038/s41419-022-05320-8 ↗
6. 10.1016/j.jare.2024.01.03310.1016/j.jare.2024.01.033 ↗
7. 10.1016/j.redox.2021.10207610.1016/j.redox.2021.102076 ↗
8. 10.1016/j.matbio.2022.11.00510.1016/j.matbio.2022.11.005 ↗
9. 10.1038/s41401-022-00927-110.1038/s41401-022-00927-1 ↗
10. Zhao Z. · MedComm · 2020 · 2025
11. 10.1016/j.semcancer.2021.05.02910.1016/j.semcancer.2021.05.029 ↗
12. 10.1379/1466-1268(2001)006<0345:IEOCCC>2.0.CO;210.1379/1466-1268(2001)006<0345:IEOCCC>2.0.CO;2 ↗
13. Tanic N. · Anticancer Res. · 2006 · 26 · 2137
14. 10.1111/j.1365-2605.2011.01169.x10.1111/j.1365-2605.2011.01169.x ↗
15. 10.1172/JCI9043910.1172/JCI90439 ↗
16. 10.1002/pmic.20180015710.1002/pmic.201800157 ↗
17. 10.1186/s12967-024-05284-710.1186/s12967-024-05284-7 ↗
18. 10.3389/fimmu.2021.69114210.3389/fimmu.2021.691142 ↗
19. 10.1016/j.clinre.2022.10191310.1016/j.clinre.2022.101913 ↗
20. 10.1186/s12885-022-10312-010.1186/s12885-022-10312-0 ↗
21. 10.1093/emboj/21.7.173310.1093/emboj/21.7.1733 ↗
22. 10.1101/gad.10.12.144310.1101/gad.10.12.1443 ↗
23. 10.1074/jbc.M61187120010.1074/jbc.M611871200 ↗
24. 10.1186/s13046-020-01690-z10.1186/s13046-020-01690-z ↗
25. Darby I. A. · Clin. Cosmet. Investig. Dermatol. · 2014 · 7 · 301
26. 10.1186/s12943-020-01278-310.1186/s12943-020-01278-3 ↗
27. 10.1186/s12885-017-3958-110.1186/s12885-017-3958-1 ↗
28. Wang Y. · Gynecol. Obstet. Invest. · 2025 · 90 · 3010.1159/000545205 ↗
29. 10.2147/OTT.S22923110.2147/OTT.S229231 ↗
30. 10.1371/journal.pone.027985110.1371/journal.pone.0279851 ↗
31. 10.1007/s11845-023-03357-y10.1007/s11845-023-03357-y ↗
32. 10.1080/15384047.2023.228712210.1080/15384047.2023.2287122 ↗
33. 10.1210/endocr/bqab21210.1210/endocr/bqab212 ↗
34. 10.1007/s10620-021-07188-810.1007/s10620-021-07188-8 ↗
35. 10.1016/j.intimp.2021.10758510.1016/j.intimp.2021.107585 ↗
36. 10.1007/s13311-019-00826-010.1007/s13311-019-00826-0 ↗
37. 10.1126/science.aaw547310.1126/science.aaw5473 ↗
38. 10.7554/eLife.7192910.7554/eLife.71929 ↗
39. 10.1158/2159-8290.CD-20-148410.1158/2159-8290.CD-20-1484 ↗
40. 10.1002/cac2.1241410.1002/cac2.12414 ↗
41. 10.1016/j.cellsig.2024.11146210.1016/j.cellsig.2024.111462 ↗
42. 10.1038/nature1298610.1038/nature12986 ↗
43. 10.1021/jacs.2c1273210.1021/jacs.2c12732 ↗
44. 10.1016/j.tcb.2022.07.00610.1016/j.tcb.2022.07.006 ↗
45. 10.1038/s41388-021-01957-510.1038/s41388-021-01957-5 ↗
46. 10.1002/cac2.1227410.1002/cac2.12274 ↗